secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001628280-26-016238
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026
--------------------------------------------------------------------------------

- Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.
- Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.
- Cash and cash equivalents $261.3M; expected cash runway at least into 2028.
- LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.
- Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/0001628280-26-016238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adc-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer